Abstract
While progesterone is a known differentiation-inducing factor in the human endometrium, for the breast epithelium both proliferation-inducing and -inhibiting effects have been described. Cyclin D1, which is required for cell cycle progression in G1 and has been shown to play an important role in the pathogenesis of breast cancer has been implicated as a possible mediator of such effects. In the present study we thus investigated the effects of the progestin agonist MPA (medroxy-progesterone acetate) on proliferation of T47D breast cancer cells. In parallel experiments, the regulation of the human cyclin D1 promoter as well as cyclin D1 protein levels under the influence of MPA were studied. Our results show an increase of proliferative activity in T47D cells after 24 and 48 h of MPA treatment follwed by inhibition of proliferation after 72 h. In Western blot analysis an increased expression level of cyclin D1 protein can be observed after 24 h of MPA stimulation, while at 72 h the protein levels are barely detectable. Transient transfection experiments with a luciferase reporter plasmid containing the human cyclin D1 promoter showed an induction of the promoter after 24 and 36 h of MPA treatment followed by a reduction in promoter activity. In conclusion, our results confirm the existence of a biphasic response of T47D cell proliferation in response to MPA treatment, consisting of stimulation of proliferation followed by inhibition, and further implicate cyclin D1 as a mediator of these effects, since the cyclin D1 promoter shows a similar biphasic response in this context.
Similar content being viewed by others
References
Horwitz KB: The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer. Endocr Rev 13: 146–163, 1992
Haslam SZ: Progesterone effects on deoxyribonucleic acid synthesis in normal mammary glands. Endocrinology 122: 464–470, 1988
Imagawa W, Tomooka Y, Hamamoto S, Nandi S: Stimulation of mammary epithelial cell growth in vitro: interactions of epidermal growth factor and mammogenic hormones. Endocrinology 116: 1514–1520, 1985
Nagasawa H, Aoki M, Sakagami N, Ishida M: Medroxyprogesterone acetate enhances spontanous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat 12: 59–66, 1988
Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Pasqualini CD: Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 17: 33–39, 1990
Robinson SP, Jordan VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene – induced rat mammary carcinoma model. Cancer Res 47: 5386–5393, 1987
Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin d1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812–821, 1993
Sherr CJ: Cancer cell cycles. Science 274: 1672–1677, 1996
Betticher DC: cyclin d1, another molecule of the year. Ann Oncol 7: 223–225, 1996
Quelle DE, Ashmun RA, Shurtleff SA: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559–1571, 1993
Wang TC, Cardiff RD, Zukerberg L: mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669–671, 1994
Zhou P, Jiang W, Zhang YJ: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571–580, 1995
Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413–7417, 1987
Herber B, Truss M, Beato M, Müller R: Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9: 1295–1304, 1994
Said TK, Coneely OM, Medina D, O'Malley BW, Lydon JP: Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endo 138: 3933–3940, 1997
Bodrug SE, Warner BJ, Bath ML: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13: 2124–2130, 1994
Lovec H, Grzeschiczek A, Kowalski MB: Cyclin D1/blc-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13: 3847–3495, 1994
Zwijsen RM, Klompmaker R, Wientjens RB, van der Sman J, Bernards R, Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405–414, 1997
Van Diest PJ, Michalides RJ, Jannink I, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: Cyclin D1 expression in invasive breast cancer. Am J Pathol 150: 705–711, 1997
Vignon F, Bardon S, Chalbos D, Rochefort H: Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab 56: 1124–1130, 1983
Horwitz KB, Freidenberg GR: Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res 45: 167–173, 1985
Musgrove EA, Lee CS, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: 5023–5043, 1991
Alkhalaf M, Murphy LC: Regulation of c-jun and jun-B by progestins in T47D human breast cancer cells. Mol Endocrinol 6: 1625–1633, 1992
Kalhoven E, Kwakkenbos-Isbrucker L, Mummery CL, de Laat SW, van den Eijnden van Raaij AJ, van der Saag PT, van der Burg B: The role of TGF-beta production in growth inhibition of breast-tumor cells by progestins. Int J Cancer 29: 80–86, 1995
Groshong SD, Owen GI, grimison B, Schauer IE, Todd MC, Langan TA, Scalfani RA, Lange CA, Horwitz KB: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip1). Mol Endocrinol 11: 1593–1607, 1997
Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL: growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577–3587, 1993
Musgrove EA, Lee CS, Buckley MF, Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91: 8022–8026, 1994
Musgrove EA, Swabrick A, Lee CS, Cornish AL, Sutherland RL: Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 18: 1812–1825, 1998
Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 84: 533–538, 1999
Rights and permissions
About this article
Cite this article
Thuneke, I., Schulte, H.M. & Bamberger, AM. Biphasic effect of medroxyprogesterone-acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells. Breast Cancer Res Treat 63, 243–248 (2000). https://doi.org/10.1023/A:1006432600478
Issue Date:
DOI: https://doi.org/10.1023/A:1006432600478